Tissue-Specific Regulation of Sex Hormone Biosynthesis and Metabolism: Novel Aspects on Hormonal Signalling and Maintenance of Cellular Steroid Levels by Maria Norlin & Kjell Wikvall
Selection of our books indexed in the Book Citation Index 
in Web of Science™ Core Collection (BKCI)
Interested in publishing with us? 
Contact book.department@intechopen.com
Numbers displayed above are based on latest data collected. 
For more information visit www.intechopen.com
Open access books available
Countries delivered to Contributors from top 500 universities
International  authors and editors
Our authors are among the
most cited scientists
Downloads
We are IntechOpen,
the world’s leading publisher of
Open Access books
Built by scientists, for scientists
12.2%
122,000 135M
TOP 1%154
4,800
18 
Tissue-Specific Regulation of Sex  
Hormone Biosynthesis and Metabolism:  
Novel Aspects on Hormonal Signalling and 
Maintenance of Cellular Steroid Levels  
Maria Norlin and Kjell Wikvall 
Department of Pharmaceutical Biosciences,  
Uppsala University, Uppsala,  
Sweden 
1. Introduction 
In this chapter, we intend to review our recent research in the context of contemporary 
research in the field of sex hormone biosynthesis and metabolism. Our findings have 
revealed novel aspects on the regulation of sex hormone metabolism and the metabolic 
control of cellular levels and effects of estrogens, androgens and neurosteroids. We will 
discuss our results in relation to current knowledge of metabolism and actions of estrogens 
and androgens. First, an introduction to this research field will be given. 
2. Sex hormones: Biosynthesis, metabolism and actions 
2.1 Biosynthesis and metabolism of sex hormones: An introduction  
The sex hormones, estrogens and androgens, are present in almost all tissues and affect such 
diverse processes as bone formation, sexual function, brain development, cardiovascular 
and immune systems and growth of various organs (Arnal et al., 2007; Cheskis et al., 2007; 
Folkerd et al., 2010; Li & Al-Azzawi, 2009). One of the tissues, where hormonal control of 
growth is essential, is the prostate, where androgens as well as estrogens play a role (Prins & 
Korach, 2008; Weihua et al., 2002). Although the physiological levels are different, both 
androgens and estrogens are needed in both sexes. 
The biosynthesis and metabolism of estrogens and androgens involve many different 
enzymes expressed in multiple organs (Miller et al., 2008; Norlin, 2008; Simard et al., 2005; 
Vihko et al., 2006). Large amounts of steroids, including sex hormone precursors are 
enzymatically formed in the adrenals, using cholesterol as starting material, and secreted to 
the circulation (Fig. 1). The formed sex hormone precursors may then be taken up by gonads 
and other organs for further metabolism to different androgenic and estrogenic compounds. 
The most important precursors for sex hormones are androstenedione and 
dehydroepiandrosterone (DHEA) and its sulphate, DHEA-S (Fig. 1). This large-scale 
production of precursors, available for transport to other tissues, is essential for 
reproductive functions and sexual development, including the formation of genitalia 
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Fig. 1. A simplified overview on the biosynthesis of steroid hormones in the adrenal cortex. 
(Rainey et al., 2004; Sultan et al., 2001). A sex hormone precursor may undergo different 
metabolic transformations in different cells, depending on which enzymes that are 
expressed in a certain tissue and how these enzymes are regulated. In addition to the uptake 
of precursors transported from the adrenals, many tissues have the ability to carry out all 
the steps in estrogen and androgen synthesis. Thus, cell-specific needs for these hormones 
may be controlled locally in each tissue (Hudak et al., 2006; Penning et al., 2000; Tsuchiya et 
al., 2005). Local metabolism, dependent on various tissue-specific enzymes, is essential to 
achieve hormonal effects and to eliminate excess hormone from the cells. 
 
 
Fig. 2. Formation of androgens. HSD, hydroxysteroid dehydrogenases. 
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Several androgens are formed in humans (Bauman et al., 2006; Hudak et al., 2006; Weihua et 
al., 2002). A well-known androgen, testosterone, is formed in large amounts in several 
tissues, including the Leydig cells of the testes (Fig. 2). Testosterone levels are strongly 
influenced by the levels of its precursors, androstenedione and DHEA, in the blood 
circulation. Target tissues can convert testosterone into dihydrotestosterone (DHT), the most 
potent androgen, 10-fold more potent than testosterone (Fig. 2). Maintenance of adequate 
cellular levels of DHT is essential for a number of physiological processes, including sexual 
development and testicular function. 
 
 
Fig. 3. Formation of some estrogens. HSD, hydroxysteroid dehydrogenases; AKR, aldo-keto 
reductases 
The physiologically most potent estrogen is estradiol (17-estradiol). The levels of estradiol are 
dependent on the enzymatic activity of aromatase (CYP19A1) which forms estradiol from 
testosterone (Bulun et al., 2009; Simpson et al., 2002) (Fig. 3). In addition, there are several other 
endogenous estrogens that affect various organs and cells (Norlin et al., 2008; Pettersson et al., 
2008; Weihua et al., 2002; Zhu et al., 2005). Individual estrogens may be of different importance 
in different tissues. For instance, 5-androstane-3,17-diol (3-Adiol) has been described as 
particularly important for estrogenic function in the prostate (Weihua et al., 2002). An 
overview of enzymes in the formation of some estrogenic steroids is shown in Fig. 3. 
The total body levels of sex hormones are regulated by signalling from the pituitary and by 
mechanisms for excretion by the kidneys or in the bile (Bourdeau & Stratakis, 2002; Hum et 
al., 1999; Waxman & Holloway, 2009). In addition, cell-specific factors and mechanisms are 
important for regulation of the local sex hormone synthesis and elimination (Jellinck et al., 
2007; Norlin, 2008; Penning et al., 2000; Reddy, 2004). Estrogens and androgens are removed 
from the body via metabolism into inactive metabolites that are excreted in the urine and/or 
feces. Local metabolism of importance for tissue hormone levels vary for different steroids 
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and different tissues. Mechanisms believed to be of importance involve e. g. hydroxylation 
by cytochrome P450 (CYP) enzymes and conjugation with sulfate or glucuronic acid by the 
UDP-glucuronosyl transferases (UGT) and sulfotransferases (SULT) (Tang et al., 2006; 
Turgeon et al., 2001 Zhu et al., 2005) (Figs. 4 and 5). 
 
 
Fig. 4. Metabolic pathways that may  affect the levels of estradiol and estrone. Please note 
that this figure is intended as an overview of potentially important pathways and does not 
necessarily describe the situation in any particular cell. AKR, aldo-keto reductases; CYP, 
cytochrome P450; HSD, hydroxysteroid dehydrogenases; SULT, sulfotransferases; UGT, 
UDP-glucuronosyl transferases. 
 
 
Fig. 5. Metabolic pathways that may affect the cellular levels of testosterone and its 
metabolites. Please note that this figure is intended as an overview of potentially important 
pathways and does not necessarily describe the situation in any particular cell. For 
abbreviations, see legend of Fig. 4. 
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2.2 Physiological and pharmacological actions of sex hormones and sex hormone-
related compounds 
Many of the cellular effects of estrogens and androgens are mediated via the classical sex 
hormone receptors, the androgen receptor, AR, and the two estrogen receptors, ER and ER 
(Brinkmann et al., 1999; Cheskis et al., 2007; Li & Al-Azzawi, 2009; Prins & Korach, 2008). The 
actions of estrogens and androgens are often mediated via hormone-responsive sequences in 
target gene promoters, the “androgen response elements“ (ARE) and “estrogen response 
elements” (ERE). Sex hormones are also able to act via mechanisms independent of the AR and 
ER (Bryant et al., 2006; Cheskis et al., 2007; Lorenzo & Saatcioglu 2008). Such mechanisms may 
involve signal transduction pathways, for instance MAPK (mitogen-activated protein kinase) 
or PI3K (phosphoinositide 3-kinase)/Akt signal pathways. Crosstalk between proteins of these 
signal pathways and estrogen receptors also have been reported for some hormonal targets. 
Additional pathways for hormonal action are believed to be mediated by different types of 
hormone receptors located at the cell membrane. Sex hormone-related compounds used in 
therapy  include antagonists of ER and AR and selective hormone receptor modulators 
(SERMs and SARMs, respectively) (Bhasin & Jasuja, 2009; Cheskis et al., 2007; Jordan, 2007). 
Selective hormone receptor modulators function as agonists in some tissues and antagonists in 
others, resulting in different tissue-specific responses.  
Despite the essential roles of sex hormones in a large number of physiological processes, 
excess amounts of these compounds can have a negative impact and even contribute to 
disease. Adverse effects of estrogens include e. g. intrahepatic cholestasis, which may occur 
in some women using oral contraceptives or during pregnancy, where this condition can 
result in premature delivery or fetal death (Yamamoto et al., 2006). Many breast tumours are 
dependent on estrogen for growth and are reported to exhibit increased estradiol 
biosynthesis. For this reason, inhibitors of the estradiol-forming aromatase (CYP19A1) are 
routinely used in treatment of breast cancer (Chen, 1998). Furthermore, although the 
growth-inducing effect of androgens are required for formation and normal function of the 
prostate, overproduction of androgens can contribute substantially to unwanted growth of 
this tissue e. g. in malignancy. Treatment to suppress androgen action and/or formation 
have therefore proven very useful in prostate cancer therapy as well as in treatment of 
benign prostate hyperplasia (Bauman et al., 2006; Hudak et al., 2006). In general, 
transformation into malignancy may elicit changes in both sex hormone concentrations and 
effects of sex hormones on growth (Bauman et al., 2006; Vihko et al., 2006). Marked changes 
in androgen and estrogen metabolism have been reported for many malignant cells. 
However, abnormalities in hormone synthesis and metabolism are not only found in 
malignancy. Although the functions of sex hormones formed in the CNS have been much 
less studied than those of the reproductive organs, disturbed synthesis and/or metabolism 
of several brain steroids have been described in neurodegenerative disease (Cossec et al., 
2010; Schaeffer et al., 2006). 
2.3 Cell- and tissue-specific steroid metabolism – role(s) for controlling cellular levels 
and effects of sex hormones 
Steroid hormone metabolism is not the same everywhere in the body. Due to the different 
physiological demands that will arise in various tissues and during different conditions, the 
level of a certain hormone at a given time need to be carefully controlled. Also, not all cells 
need the same types of hormones. Often, a steroid hormone may potentially undergo 
several different metabolic pathways. However, one pathway may be particularly active in a 
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certain tissue but absent in another tissue where a different pathway dominates. Metabolism 
of a steroid could also lead to a host of metabolites in the same tissue, via different 
enzymatic steps, all of which can be differentially affected by endogenous or exogenous 
regulators. Consequently, since the effect(s) of a hormone are dependent on its 
concentration, the metabolic pathways in a cell or tissue can have a considerable impact on 
which cellular actions that takes place.  
An example of a steroid metabolized into many different compounds is 
dehydroepiandrosterone (DHEA) (Norlin, 2008; Rainey, 2004). This steroid is reported to 
have a number of effects of its own but, as described in the Introductory section, it is also 
essential as a precursor for a number of other hormones, with their own individual effects. 
The activity of the enzymes and genes involved in formation of these different products can 
all be differentially regulated. 
Our knowledge on the cellular metabolic events that involve steroid hormones is far from 
sufficient. A proper understanding of these events would substantially increase the 
possibilities to intervene in physiological processes involving these hormones, such as 
cellular growth, dysfunctions of the reproductive and immune systems and a number of 
processes important for brain function. Even though there is a clear link between the serum 
levels of a hormone and its physiological effect(s), the levels of hormones present in a tissue 
often differs substantially from the levels measured in serum. Unfortunately, the steroid 
levels in tissue material are much more problematical to assay than the serum levels. Other 
complicating factors are the complex interplay of enzymes and regulatory molecules leading 
to formation of a certain compound and the existence of different cell-types with specific 
properties within the same tissue. 
3. Sex hormones and vitamin D 
In recent years, vitamin D has attracted increasing attention for its ability to regulate 
numerous genes in several physiological processes. In the following sections, a brief 
overview of the vitamin D hormone and discussion of data regarding the effects on sex 
hormone biosynthesis and metabolism will be given. 
3.1 Vitamin D is activated to a multifunctional hormone with effects on gene 
expression 
The prohormone vitamin D3 (cholecalciferol) is synthesized in the skin on exposure to 
ultraviolet light and is also acquired from the diet (Holick, 1987). Vitamin D is needed for 
regulation of calcium levels in the body and vitamin D deficiency leads to skeletal diseases 
such as rickets in children and osteomalacia/osteoporosis in adults (Brown et al., 1999; 
DeLuca, 2004; Dusso et al., 2005; Jones et al., 1998). The role of vitamin D in human health 
and disease has received increased recognition in recent years. Although it was previously 
considered to be limited to regulation of calcium levels, recent data from epidemiological 
studies and basic sciences have expanded our understanding of its pivotal role in many 
biological processes. Vitamin D is important not only for endocrine functions, such as 
calcium homeostasis, but also for autocrine and/or paracrine functions, such as regulation 
of immune system, brain and fetal development, insulin secretion, apoptosis, cell 
proliferation and differentiation as well as involvement in cancer and the cardiovascular 
system. Most of these actions are mediated by transcriptional regulation of target genes 
through the vitamin D receptor (VDR), a member of the nuclear receptor superfamily of 
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transcription factors (Armas & Heaney, 2011; Atkins et al., 2007; Norman, 2006, 2008; 
Verstuyf et al., 2010).  
The active vitamin D3 hormone, 1,25-dihydroxy-vitamin D3 (calcitriol), is formed through 
metabolic bioactivation by cytochrome P450 (CYP450) enzymes (Jones et al., 1998; Prosser & 
Jones, 2004; Wikvall, 2001). The activation of vitamin D requires two sequential 
hydroxylations (Fig. 6). The first step is a 25-hydroxylation of vitamin D3 producing 25-
hydroxyvitamin D3 or calcidiol. A number of cytochrome P450-enzymes are capable of 
performing the 25-hydroxylation and in most organisms studied at least two 25-
hydroxylases have been found – the mitochondrial CYP27A1 and the microsomal CYP2R1 
(Cheng et al., 2003, 2004; Dahlbäck & Wikvall, 1988; Gascon-Barre et al., 2001). The second 
bioactivation step is a 1-hydroxylation of calcidiol producing 1,25-dihydroxyvitamin D3 
or calcitriol. The 1-hydroxylation is carried out by CYP27B1 (Fu et al., 1997). Production of 
the circulating 1,25-dihydroxyvitamin D3 is initiated by hepatic 25-hydroxylation followed 
by renal 1-hydroxylation. The circulating vitamin D hormone has mainly endocrine 
function e.g. in regulation of calcium homeostasis and maintenance of bone health.  The 
normal serum levels of 25-hydroxyvitamin D3 (20-250 nmol/L) are thousand times higher 
than the levels of 1,25-dihydroxyvitamin D3 (20-250 pmol/L). 1,25-Dihydroxyvitamin D3 
is the most potent form of vitamin D3 but 25-hydroxyvitamin D3 can exert biological effects 
as well (Lou et al., 2004, 2010; Tuohimaa et al., 2005).  
 
 
Fig. 6. Bioactivation of vitamin D3. 
Both calcidiol and calcitriol undergo further metabolism by the catabolizing enzyme 
CYP24A1 (Fig. 7). This enzyme 24-hydroxylates vitamin D metabolites and the 24-
hydroxylation is a key point at which degradation of vitamin D begins. 24-Hydroxylated 
vitamin D metabolites are less biologically active and are then further metabolized by the 
multicatalytic CYP24A1 via side chain hydroxylation and oxidation to less active substances. 
Finally, after side chain cleavage, calcitroic acid is formed. Calcitroic acid is then excreted 
into the bile (Makin et al., 1989; Reddy and Tserng, 1989; Zimmerman et al., 2001).  
The expression of both the activating (25- and 1-hydroxylases) and the catabolizing (24-
hydroxylase) enzymes by cells of certain tissues, indicates that the multifunctional hormone 
1,25-dihydroxyvitamin D3 can be produced locally in some tissues, including cells in the 
skin, breast, colon, prostate, lung, and various cells of the immune system. The intracellular 
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Fig. 7. Metabolism of 1,25-dihydroxyvitamin D3 (calcitriol) by CYP24A1 into less active 
metabolites. 25-Hydroxyvitamin D3 is also catabolized by CYP24A1 in a similar way. 
1,25-dihydroxyvitamin D3 is mainly used in an autocrine manner as a cofactor in the 
expression of many genes. This autocrine 1,25-dihydroxyvitamin D3 binds to VDR and 
modifies gene transcription. For example, genes involved in cell proliferation, differentiation 
and apoptosis are believed to be regulated by the internal 1,25-dihydroxyvitamin D3 of the 
cell. The activation, effects on gene expression and inactivation of 1,25-dihydroxyvitamin 
D3, is contained within the host cell. This active form of vitamin D is the major player in the 
internal autocrine action, but also 25-hydroxyvitamin D3 can be formed within the cell and 
regulate gene expression (Lou et al., 2004; Tuohimaa et al., 2005; Verstuyf et al., 2010).  
Recent data have revealed that vitamin D deficiency in the general population and even 
among young and healthy people is much more common than previously believed. Vitamin 
D deficiency not only causes rickets among children but also precipitates and exacerbates 
osteoporosis among adults and causes the painful bone disease osteomalacia. Interestingly, 
vitamin D deficiency is associated with increased risks of cardiovascular disease, multiple 
sclerosis, rheumatoid arthritis, type 1 diabetes mellitus and deadly cancers, such as prostate, 
breast and colon cancers (Adorini, 2002; Armas & Heaney, 2011; Giovannucci, 2007; Pérez-
López, 2008; Schwartz, 2005; Zittermann, 2003).  
The vitamin D receptor is widely expressed and it has been suggested that the active 
vitamin D3 hormone may affect the expression of up to 200 genes in humans (Jones et al., 
1998; Norman, 2008; Ramagopalan et al., 2010). It is probable that vitamin D3 may have other 
roles yet undiscovered.  
3.2 Vitamin D3 exerts tissue-specific effects on estrogen and androgen metabolism 
In recent reports from our laboratory, data are presented revealing vitamin D-mediated 
effects on the production of steroid hormones and expression of crucial steroidogenic 
enzymes in various cell lines (Lundqvist et al., 2010, 2011). As an example, the active 
vitamin D hormone 1,25-dihydroxyvitamin D3 decreases the production of 
dehydroepiandrosterone (DHEA) and DHEA-sulphate in adrenocortical NCI-H295R cells. 
DHEA is a precursor for both estrogen and androgen production. mRNA levels and enzyme 
activities for key enzymes in the steroidogenesis, such as CYP17A1 and CYP21A2 (cf. Fig. 1), 
were found to be altered by 1,25-dihydroxyvitamin D3 treatment (Lundqvist et al., 2010).  
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Fig. 8. Some important enzyme reactions in androgen and estrogen metabolism. 
Accumulated data have revealed that sex hormone biosynthesis and metabolism may be 
regulated by vitamin D (Barrera et al., 2007; Krishnan et al., 2010; Lou et al., 2005; Lundqvist et 
al., 2011; Tanaka et al., 1996). Important reactions in the metabolism of androgens and 
estrogens are catalyzed by 5-reductase and aromatase (CYP19A1) (Fig. 8). These two key 
enzymes determine the balance between androgen production and estrogen production. In 
addition to 5-reductase and aromatase, the 17-hydroxysteroid dehydrogenases are enzymes 
which regulate intracellular concentrations of active sex steroid hormones. Calcitriol has been 
found to up-regulate some types of 17-hydroxysteroid dehydrogenase in human prostate 
cancer LNCaP and PC3 cells but not in stromal cells (Wang & Tuohimaa, 2007).  
Estrogens are produced from androgenic precursors in a reaction catalyzed by aromatase 
(CYP19A1) (Figs. 3 and 8). Calcitriol increases aromatase activity in placental cells (Barrera 
et al., 2007), prostate cells (Lou et al., 2005) and osteoblasts (Tanaka et al., 1996) and vitamin 
D receptor null mutant mice have a decreased aromatase activity in the ovary, testis and 
epididymis (Kinuta et al., 2000). Interestingly, it was recently reported that 1,25-
dihydroxyvitamin D3 regulates the expression of aromatase in a tissue-selective manner. 
Thus, calcitriol significantly decreased aromatase expression in human breast cancer cells 
and adipocytes but caused increased aromatase expression in human osteosarcoma cells and 
ovarian cancer cells (Krishnan et al., 2010). Calcitriol exerts cell line-specific effects on both 
estrogen and androgen metabolism, including the production of estrogens and androgens 
(Lundqvist et al., 2011). In breast cancer MCF-7 cells, aromatase gene expression and 
estradiol production were decreased, while production of androgens was markedly 
increased. In human adrenocortical NCI-H295R cells, 1,25-dihydroxyvitamin D3 stimulated 
aromatase expression and decreased dihydrotestosterone production. In prostate cancer 
LNCaP cells, aromatase expression increased after the same treatment, as did production of 
testosterone and dihydrotestosterone (Table 1). These findings are of interest for the 
research fields of breast cancer and prostate cancer. Vitamin D seems to be involved in the 
control also of prostate cancer cell growth (Flanagan et al., 2010; Tuohimaa et al., 2005). 
Analysis of effects of 1,25-dihydroxyvitamin D3 on aromatase promoter activities revealed 
differences between NCI-H295R cells and MCF-7 cells, where promoter I.3 and promoter I.4 
were stimulated and promoter II were down regulated in NCI-H295R cells (Lundqvist et al., 
2011) while all three promoters are down regulated in breast cancer MCF-7 cells (Krishnan 
et al., 2010). 
The findings that 1,25-dihydroxyvitamin D3 specifically down regulates aromatase gene 
expression and activity and decreases production of estradiol in breast cancer cells are 
interesting in the context of 1,25-dihydroxyvitamin D3 as an anti cancer agent (Krishnan et 
al., 2010, Lundqvist et al., 2011) 
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Table 1. Effects of calcitriol on estrogen and androgen metabolism. Please note that this table 
only summarizes the data obtained by our group (Lundqvist et al., 2011). Arrows indicate 
up- and down-regulation; -, unaltered. 
Interestingly, 1,25-dihydroxyvitamin D3 increases androgen production in breast cancer 
MCF-7 cells (Lundqvist et al., 2011). The production of testosterone was increased by 60% 
and the production of dihydrotestosterone was increased 4-fold. The markedly increased 
production of dihydrotestosterone in MCF-7 cells after 1,25-dihydroxyvitamin D3 
treatment appears not to be the result of increased 5-reductase expression. An explanation 
for this effect could be that the decreased aromatase activity increases the concentration of 
testosterone, which is the precursor for dihydrotestosterone. The increased androgen 
production in breast cancer cells following vitamin D treatment needs to be studied further 
to elucidate its potential physiological roles.  
The data showing that 1,25-dihydroxyvitamin D3 exerts tissue-specific effects on sex 
hormone production and metabolism provide important knowledge for further research in 
the fields of prostate and breast cancer. Prostate and breast are key tissues for estrogenic and 
androgenic pathways. Vitamin D deficiency is associated with increased risks of prostate 
and breast cancers (Holick, 2006; Thorne & Campbell, 2008; Bouillon et al., 2006). It is well-
known that the active form of vitamin D, 1,25-dihydroxyvitamin D3, and analogs via 
binding to the vitamin D receptor exert anti-proliferative and pro-differentiative effects and 
have therefore been proposed to be of potential use as anti cancer agents (Deeb et al., 2007; 
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Masuda & Jones, 2006). Estrogens and androgens play a role in the pathogenesis of prostate 
cancer and a large group of all breast cancers involves estrogen-dependent mechanisms, i.e. 
they rely on estrogens to proliferate (Mathiasen et al., 2002; Sasano et al., 2009). The recent 
findings indicating regulation of intracellular levels of androgens and estrogens by vitamin 
D open new possibilities in prevention and treatment of prostate and breast cancer.  
Aromatase (CYP19A1), the enzyme catalyzing the conversion of testosterone to estradiol, is 
critical for the progression of estrogen receptor-positive breast cancer in postmenopausal 
women. The aromatase expression is higher in breast cancer tissue than in normal breast 
tissue and the local estrogen levels in breast cancer tissue are higher than the circulating 
levels (Chen, 1998; Miller et al., 1990). Regulation of estradiol production and estrogenic 
signalling are key strategies in breast cancer treatment. Aromatase inhibitors and 
antiestrogens have therefore become important drugs in breast cancer treatment. Due to its 
effects on aromatase gene expression and enzyme activity, 1,25-dihydroxyvitamin D3 has 
been proposed as an interesting substance in breast cancer treatment and prevention. The 
vitamin D-mediated inhibition of aromatase seems to be tissue specific for breast cells, 
indicating that it is a potential drug target in treatment aiming to prevent estradiol 
production in breast but not in other tissues. This would reduce the risk of adverse effects 
due to effects on peripheral estrogen metabolism (e.g. osteoporosis). The vitamin D-induced 
tissue-selective regulation of aromatase expression and activity is an interesting strategy to 
affect estrogen levels in breast without effects on the peripheral estrogen metabolism. 
High-dose vitamin D treatment will lead to adverse effects e.g. hypercalcemia. Therefore, 
synthetic vitamin D analogs with less pronounced hypercalcemic effect are potential drugs 
in treatment aiming to prevent estradiol production in breast but not in other tissues, a 
strategy that would lead to less adverse effects than the existing treatments. However, the 
mechanisms for these effects of vitamin D need to be clarified before vitamin D or analogs 
can be used in breast cancer treatment. It has been reported that the vitamin D analog 
EB1089 decreases the proliferation of breast cancer cells, especially anti-estrogen resistant 
breast cancer cells (Christensen et al., 2004; Larsen et al., 2001). EB1089 has undergone 
clinical trials phase I and II and was found to be a well tolerated substance (Dalhoff et al., 
2003). However, it has not yet been tested in clinical trials against breast cancer. The new 
findings on vitamin D as a tissue-selective modulator of aromatase reinforce the interest for 
EB1089 as a potential drug in treatment of breast cancer, which may inhibit both estrogen-
dependent and anti-estrogen resistant breast cancer. 
Human adrenocortical NCI-H295R cells are widely used as a model for human adrenal 
cortex. It has been proposed that this adrenocortical carcinoma cell line could be suitable in 
a screening assay to study the effects of different chemicals on estradiol and testosterone 
production (Gracia et al., 2006; Hecker et al., 2006, 2007; Higley et al, 2010). We have 
examined whether adrenocortical NCI-H295R cells react in the same way as prostate cells 
and breast cells when they are treated with 1,25-dihydroxyvitamin D3. Interestingly, both 
estrogen and androgen metabolism were affected in a cell line-specific way (Table 1). The 
largest differences were observed between NCI-H295R cells and MCF-7 cells, where 
aromatase gene expression, estradiol production, aromatase promoter activity, testosterone 
production and dihydrotestosterone production were affected in opposite ways in the two 
cell lines. The discrepancies between NCI-H29R cells and LNCaP cells were smaller, but still 
noteworthy. Production of both testosterone and dihydrotestosterone was affected 
differentially in the two cell lines, as was the gene expression of 5-reductase. Our data 
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show that NCI-H295R cells respond in a different way than cells derived from important 
target tissues in estrogen and androgen production and metabolism (Lundqvist et al., 2011). 
These differences between NCI-H295R cells and cells derived from key endocrine target 
tissues need to be addressed and clarified if NCI-H295R cells should be used as a model for 
effects of different chemicals on estrogen and androgen metabolism. 
4. Actions of CYP7B1 - potential role(s) for the levels and effects of 
estrogens, androgens and neurosteroids 
In recent years we have carried out several studies on the effects and regulation of catalytic 
reactions mediated by CYP7B1, a widely expressed enzyme with a number of steroid 
substrates including DHEA. CYP7B1-mediated catalysis leads to formation of 6- or 7-
hydroxymetabolites, mainly 7-hydroxyderivatives (Pettersson et al, 2008; Rose et al., 1997; 
Tang et al., 2006; Stiles et al., 2009; Wu et al., 1999) (Fig. 9). This enzyme has been associated 
with several physiological processes, including brain function, immune system, cholesterol 
homeostasis and cellular viability and growth. Scientific publications in various areas have 
linked altered CYP7B1 levels and/or function to neurodegenerative processes, arthritis, and 
prostate cancer (Dulos et al., 2004; Olsson et al., 2007; Tsaousidou et al., 2008; Yau et al., 
2003). However, the manner in which CYP7B1 affects these processes are in many cases 
unclear.  
 
 
Fig. 9. CYP7B1-mediated catalytic reactions. 
Substrates for CYP7B1 are neurosteroids, cholesterol derivatives and sex hormones, 
including some of the ligands for the estrogens receptors (ER). In recent studies we 
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examined the role of CYP7B1-mediated catalysis for activation of the ER (Pettersson et al., 
2008, 2010). Our studies, using ER-dependent luciferase reporter systems and ER-target 
genes, indicate significant stimulation of ER-response by the CYP7B1 substrates 5-
androstene-3,17-diol (Aene-diol) and 5-androstane-3,17-diol (3-Adiol), for both ER 
and . In contrast, the CYP7B1-formed metabolites from these steroids have little or no 
estrogenic effects, indicating that CYP7B1-mediated metabolism abolishes the ER-
stimulating effect of these compounds (Pettersson et al., 2010). In the course of our studies 
we have also found that DHEA induces both ER-dependent and AR-dependent responses in 
some cell types whereas 7-hydroxy-DHEA has no or diminished effect (Norlin M. & 
Lundqvist J., unpublished results).  
Our findings seem to indicate that actions by CYP7B1 might be a way to decrease estrogenic 
response, at least in some tissues. One of these may be the prostate, where signalling via 
ER has been reported to play a role in growth suppression. Gustafsson and collaborators 
proposed a pathway for hormonal control of proliferation where the role of CYP7B1 would 
be to counteract anti-proliferative action of ER by metabolizing its ligand 3-Adiol (Weihua 
et al., 2002). This concept is supported by findings indicating that prostates of CYP7B1-/- 
mice are hypoproliferative. The roles of estrogens and estrogen receptors in prostate growth 
are however not well understood (Morani et al., 2008; Prins & Korach, 2008). Interestingly, 
Olsson et al. (2007) reported high expression of CYP7B1 protein in human high-grade 
prostatic intraepithelial neoplasia and adenocarcinomas. Enzymatic events of potential 
importance for intraprostatic hormone levels are of course not limited to actions by CYP7B1. 
Other enzymes of relevance include e. g. the conjugating enzymes, particularly some of the 
UDP-glucuronosyltransferases (UGT) expressed in prostate (Barbier & Bélanger, 2008). Also, 
the enzymes known to form important hormones in this tissue such as CYP17A1, 5-
reductase and the 3- and 17-hydroxysteroid dehydrogenases have attracted interest as 
potential or existing targets for therapy aimed at controlling cellular hormone levels (Hudak 
et al., 2006; Norlin; 2008; Sharifi, 2010; Vihko et al., 2006). 
Considering its role in metabolism of ER ligands, CYP7B1 has been linked to estrogenic 
action by several studies and investigators (Petterson et al., 2010; Sugiyama et al., 2009; 
Weihua et al., 2002). However, the actions of CYP7B1 in sex hormone metabolism do not 
seem to be limited to estrogenic signalling. For instance, some of the steroids that are 
substrates for this enzyme may affect both estrogen and androgen receptors. This includes 
DHEA and Aenediol which are reported to be able to trigger both ER and AR signalling. It 
seems likely that the actual effects of these steroids in vivo may strongly depend on their 
local concentration. In addition, the presence or absence of other hormone ligands with 
higher affinitity for the receptor as well as the effects of tissue-specific comodulators should 
play important roles. These different possibilities open for enzymatic control of cell-specific 
actions, depending on e. g. comodulator expression, substrate availability, and  substrate 
competition (Pettersson et al., 2008; Shapiro et al., 2011; Sugiyama et al., 2009).  
The most potent androgenic hormone in the human body is dihydrotestosterone (DHT). 
Maintenance of normal DHT levels is essential for a number of physiological processes. On 
the other hand, excess levels of androgens, which strongly stimulate growth, may have a 
negative impact in disease. We recently identified a previously unknown androgenic 
substrate for CYP7B1 which is a metabolite of DHT (Pettersson et al., 2009) (Fig. 10). This 
steroid, 5-androstane-3,17-diol (3-Adiol), can itself induce androgenic responses, but 
since the effects of 3-Adiol are weaker that those of DHT, conversion into 3-Adiol is 
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considered a means to reduce DHT-mediated effects on cell growth and other processes. 3-
Adiol can easily be converted back to DHT and is believed to serve as a source for this 
hormone (Auchus, 2004; Penning et al., 2000). 3-Adiol is also believed to be of importance in 
the CNS, where it can modulate the action of gamma-amino butyric acid A (GABAA) receptors 
and is reported to have anticonvulsant and analgesic properties (Reddy 2004; Frye, 2007).  
 
 
Fig. 10. CYP7B1-mediated metabolism of 5-androstane-3,17-diol (3-Adiol) 
Local formation and functions in the CNS are features shared by other, previously 
characterized, substrates for CYP7B1, including DHEA, pregnenolone, Aenediol and 27-
hydroxycholesterol, a cholesterol derivative believed to serve as a regulator of cholesterol 
homeostasis (Norlin & Wikvall 2007, Pikuleva; 2006). An important role for CYP7B1 in brain 
physiology is indicated by the recent studies revealing that disturbed function of this 
enzyme is linked to a human motor-neuron degenerative disease. Tsaousidou et al. (2008) 
first showed that hereditary spastic paraplegia (HSP) is associated with mutations in the 
CYP7B1 gene. Mutations in the coding region of this gene, which affects the functionality of 
the enzyme, is believed to be a frequent cause of this disease. The etiology and molecular 
mechanisms that underlies hereditary spastic paraplegia are however not known. It has 
been proposed that the mutated forms of CYP7B1 in patients suffering from HSP might lead 
to an abnormal brain cholesterol homeostasis due to an increase in 27-hydroxycholesterol 
levels (Tsaousidou et al., 2008). Despite the role of this steroid for maintenance of cholesterol 
homeostasis, 27-hydroxycholesterol negatively affects viability of some cells (Dasari et al., 
2010). This steroid can also modulate estrogen receptor signalling in some tissues and has 
been described as an endogenous SERM (Du Sell et al. 2008; Umetani et al., 2008) However, 
it is also possible that the pathogenic basis for hereditary spastic paraplegia is connected to 
abnormal levels of other CYP7B1 substrates present in the brain, including DHEA. Although 
there is still much to be learned in this field, brain steroids are believed to influence several 
aspects of CNS function (Charalampopoulos et al., 2006; Maninger et al., 2009; Melcangi & 
Panzica, 2006). Various neurosteroids are considered to be involved in e. g. neuronal 
development, regulation of inflammatory responses, effects on cellular viability and 
modulation of the actions of various neurotransmitter receptors.  
The concept of widely varying cell- and tissue-specific steroid metabolism is illustrated by 
the differences in metabolism of DHEA in different CNS cell types. Thus, whereas rat 
microglia, a cell type important for brain immune function, is reported to exclusively 
convert this steroid to Aenediol, the major route for DHEA metabolism in rat astrocytes 
seems to be 7-hydroxylation, carried out by CYP7B1 (Fex Svenningsen et al., 2011; Jellinck 
et al., 2001; Jellinck et al, 2007). In contrast, the pathways using DHEA as an obligatory 
precursor for formation of testosterone and estradiol (see Introductory section), are much 
more dominant in cells outside the brain and are indeed essential for the development and 
functions of many endocrine organs. Very recently, we found that treatment with 
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endogenous and synthetic estrogens strongly decreases CYP7B1-mediated DHEA 
hydroxylation in primary cultures of rat astrocytes (Fex Svenningsen et al., 2011). Since 
CYP7B1-mediated metabolism appears to be the main pathway for DHEA metabolism in 
these cells, we believe that estrogenic effects on this enzyme may lead to increase of the 
levels of DHEA via suppression of its metabolism. This could be one of the potential 
mechanisms whereby estrogens affect CNS, and may play a role for estrogen-dependent 
protection of CNS cells against injury (Brann et al., 2007; Melcangi & Panzica 2006).  
5. Role of sex hormones in regulation of steroid-metabolizing enzymes 
5.1 CYP7B1 is regulated by sex hormones 
Our studies, carried out in several different cell types, indicate regulatory effects of both 
estrogen and androgens on CYP7B1 expression (Fex Svenningsen et al., 2011; Tang et al., 
2006; Tang & Norlin, 2006) (Fig. 11). As described in the previous section, our results in 
primary rat CNS cultures showed decreased CYP7B1-mediated catalytic activity following 
estrogen treatment (Fex Svenningsen et al., 2011). In the studies on astrocytes we also found 
suppressive effects of estrogen on CYP7B1 mRNA levels. These findings, indicating 
suppression of the CYP7B1 gene, are different compared to some of our previous data 
concerning estrogen-dependent regulation of CYP7B1 in human kidney- and liver-derived 
cell lines (Tang et al., 2006, 2008). In kidney-derived HEK293 cells and liver-derived HepG2 
 
 
* Involvement of the PI3K/Akt pathway (Tang et al., 2008) 
Fig. 11. Simplified overview of our findings on the effects of estrogens on the  regulation of 
CYP7B1 in different cell types. For more information see text and references (Tang et al., 
2006, 2008; Tang & Norlin, 2006; Fex Svenningsen et al., 2011)  
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cells, we have found that estradiol up-regulates CYP7B1 gene expression in the presence of 
estrogen receptors. Without overexpression of ER however, the kidney HEK293 cells, which 
have very low endogenous ER expression, react similarly as the astrocytes to estradiol 
treatment, suggesting that there might be both ER-dependent and ER-independent pathways 
for estrogen-mediated regulation of CYP7B1. Other possibilities are tissue- and/or species-
specific differences in regulatory mechanisms. Species differences in enzymes may include 
enzyme localization. Data obtained by us and others show higher CYP7B1 levels in rat 
astrocytes than in rat neurons, whereas in humans CYP7B1 expression has been reported to be 
predominantly located in neurons (Fex Svenningsen et al., 2011; Trap et al., 2005; Zhang et al., 
1997). However, in similarity with our results in human renal and hepatic cells, estrogen 
receptor-mediated upregulation of CYP7B1 has been shown also in mouse kidney and liver, 
indicating a similar effect in rodents as in humans and supporting an in vivo role for this 
regulatory mechanism (Jelinsky et al., 2003; Yamamoto et al., 2006).  
Thus, from the results obtained by us and other investigators it seems that CYP7B1 not only 
affects hormonal actions but is itself regulated by hormones. Our studies have shown effects 
on CYP7B1 transcription and/or activity by both estrogens and androgens, although we 
observed differences depending on cell type (Fex Svenningsen et al., 2011; Tang et al., 2006, 
2008; Tang & Norlin 2006). This may reflect different  functions of CYP7B1 in different 
tissues or cells. In cell types where formation of estradiol is quantitatively important, the 
observed ER-mediated induction by estradiol on the CYP7B1-mediated pathway may be a  
means to divert DHEA from estradiol production, by increasing the amount of DHEA 
metabolized to 7-hydroxyDHEA (Tang et al., 2006) (Fig. 12). In this way, estradiol-
mediated regulation of CYP7B1 may decrease the levels of DHEA available for synthesis of 
estradiol in some tissues, functioning as a feed-back mechanism to balance the amount of 
estradiol formed. This could be of particular importance during fetal development as 
placental estrogen formation is dependent on C19-steroid precursors such as DHEA which is 
secreted in large amounts by the fetal adrenal cortex. Although there are few data on the 
role(s) of CYP7B1 in fetal development, studies on tissues from both humans and rodents 
show markedly higher CYP7B1 mRNA levels in extrahepatic fetal tissues compared with the 
corresponding adult ones (Bean et al., 2001; Tang et al., 2006).  
 
 
Fig. 12. Some of the alternate pathways for DHEA metabolism 
Our data on estrogen-mediated upregulation of the CYP7B1 gene promoter in liver-derived 
human HepG2 cells showed involvement of the Akt/PI3K (phosphoinositide 3-kinase) 
cascade in the ER-mediated effects on CYP7B1 (Tang et al., 2008). The link between CYP7B1 
and this signalling pathway, which is known to be of importance for cellular survival, 
suggests a possible connection between CYP7B1 action and viability. Also, as outlined 
www.intechopen.com
Tissue-Specific Regulation of Sex Hormone Biosynthesis and Metabolism:  
Novel Aspects on Hormonal Signalling and Maintenance of Cellular Steroid Levels 
 
391 
above, studies on this enzyme in the CNS point towards a potential role connected to 
neuroprotective events (Bean et al., 2001; Fex Svenningsen et al., 2011; Tsaousidou et al., 
2008). Although CYP7B1 expression is abundant in tissues of humans and animals most 
immortalized cell lines lose their expression of CYP7B1. The reason for this is not known.  
The estrogen-mediated regulation of CYP7B1 is of interest also because this enzyme 
catabolizes 27-hydroxycholesterol, recently identified as the first endogenous selective 
estrogen receptor modulator, SERM (Fig. 13). 27-Hydroxycholesterol is produced from 
cholesterol by the sterol 27-hydroxylase CYP27A1. Interestingly, CYP27A1 is also regulated 
by estrogens and androgens. The regulation of CYP27A1 by sex hormones is discussed 
below. 
 
 
Fig. 13. Formation and metabolism of 27-hydroxycholesterol. 
5.2 CYP27A1 is regulated by sex hormones 
The sterol 27-hydroxylase CYP27A1 is an enzyme with several important roles (Norlin & 
Wikvall, 2007). CYP27A1 regulates cholesterol homeostasis including bile acid biosynthesis, 
cholesterol transport and cholesterol elimination. CYP27A1 is also a vitamin D 25-
hydroxylase, catalyzing the first step in the bioactivation of vitamin D into the 
multifunctional hormone 1,25-dihydroxyvitamin D (Fig. 6). CYP27A1 is essential for the 
production of 27-hydroxycholesterol (Fig. 13), an oxysterol which has recently been 
identified as an endogenous selective estrogen receptor modulator, SERM (DuSell et al., 
2008, 2010; Umetani et al., 2007, 2011). Considering these important functions, mechanisms 
for regulation of the human CYP27A1 gene are of great interest. 
In studies carried out by our laboratory, we found that the cellular mRNA levels, enzyme 
activity and promoter activity of CYP27A1 are regulated by estrogens and androgens 
(Norlin et al., 2011; Tang et al., 2007) (Figs. 14 and 15). The responses to sex hormones are 
different in various cell lines and cells from different tissues. The hormonal action on the 
CYP27A1 promoter appears to be complex. In addition to cell-dependent effects, there are 
also differences between receptor subtypes and different promoter deletion constructs. For 
instance, whereas ER suppressed the full-length promoter in HepG2 cells, deletion of a 3.4 
kb long part of the promoter resulted in the opposite response. On the contrary, the 
response of different promoter constructs to ER was similar. The data available indicate 
that the CYP27A1 promoter contains sequences able to mediate both stimulation and 
suppression by ER (Tang et al., 2007). ER-mediated regulation of transcription is often 
associated with binding of ER homodimers to estrogen response elements (ERE) in target 
promotors. However, regulation by ER can also involve interaction with sequences 
containing Sp1 and activator protein (AP-1) sites (Safe, 2001; Schultz et al., 2005). 
Interestingly, it has been reported that ER-mediated regulation involving AP-1 sites may 
lead to opposite effects depending on ER subtype (Paech et al., 1997). As mentioned above, 
the CYP27A1 promoter contains several putative binding sites for ER, AP-1 and Sp1. It 
seems possible that cell-specific interactions with coactivators may be the reason for the 
different effects observed with different cell types and receptor subtypes.  
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Fig. 14. Simplified overview of our findings on the effects of estrogens on the gene regu-
lation of CYP27A1 in different cell types. For more information see text and references 
(Norlin et al., 2011; Tang et al., 2007). 
Our studies on the mechanisms for the hormonal regulation of CYP27A1 have indicated the 
involvement of the JNK (c-jun N-terminal kinase)/c-jun pathway in androgen-mediated 
regulation of this enzyme (Norlin et al., 2011). It has been reported that the androgen 
receptor (AR) is phosphorylated by JNK and that stress kinase signaling regulates AR 
phosphorylation, transcription, and localization. Crosstalk between the JNK protein kinase 
and AR has been reported in several studies (Gioeli et al., 2006; Lazarevic et al, 2008; 
Lorenzo & Saatcioglu, 2008;). The link to JNK signaling is interesting since inflammatory 
processes, which can induce the JNK/c-jun pathway, may upregulate CYP27A1 to clear 
cholesterol from peripheral tissues. 
The findings that estrogens downregulate and androgens upregulate CYP27A1 expression 
in liver-derived HepG2 cells are of interest for several reasons (Tang et al., 2007). The results 
are consistent with reports on an increased risk for cardiovascular disease in 
postmenopausal women treated with estrogen plus progestin. Also, increased testosterone 
levels in men have been associated with a favorable lipid profile (Alexandersen & 
Christiansen, 2004; Steinberg, 2006; Stoll & Bendszus, 2006; Tchernof et al., 1997; Zmuda et 
al., 1997). The difference in prevalence of atherosclerotic coronary disease between men and 
women can not be explained by effects of estrogens and androgens solely on CYP27A1 
expression. However, the effects by sex hormones on the expression of CYP27A1 may have 
impact on several processes in cholesterol homeostasis. The findings that CYP27A1 is 
regulated by sex hormones imply that endogenous sex hormones as well as pharmacological 
compounds with estrogenic and androgenic effects may have an impact on several 
processes related to CYP27A1-mediated metabolism, such as cellular survival and growth, 
CNS function and cholesterol homeostasis. Because estrogens are used in oral 
contraceptives, in hormone therapy of postmenopausal women and in cancer treatment, the 
question arises how CYP27A1 is influenced by estrogens in different tissues. This question is 
of particular interest considering that anti-atherogenic properties have been ascribed to 
CYP27A1. The possibility of a tissue-specific regulation by sex hormones is supported by 
results with prostate cancer cells where estrogen increases the CYP27A1 transcriptional 
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activity. The results also show that effects of sex hormones on CYP27A1 regulation are 
different in non-cancerous prostate RWPE-1 compared with prostate cancer LNCaP cells. 
Whether this difference in regulatory effects is due to different properties of different 
prostate cell lines or to altered properties of the CYP27A1 regulation in prostate cancer 
remain to be established. 
 
 
* Involvement of the JNK/c-jun kinase signalling pathway (Norlin et al., 2011). 
Fig. 15. Simplified overview of our findings on the effects of androgens on the gene 
regulation of CYP27A1 in different cell types. For more information see text and references 
(Norlin et al., 2011; Tang et al., 2007). 
5.3 Effects of sex hormones on vitamin D metabolism 
Activated vitamin D metabolites, that can be formed by CYP27A1, are known to have 
beneficial effects on cell growth in extrahepatic tissues, such as in prostate cells and prostate 
cancer cells. As discussed above, novel data indicate that estrogens and androgens might 
regulate the intracellular levels of active hydroxyvitamin D3 metabolites in prostate cells via 
regulation of CYP27A1 gene expression (Norlin et al., 2011; Tang et al., 2007). Another 
observation indicating that androgens can influence intracellular levels of active vitamin D 
metabolites was reported some years ago  (Lou and Tuohimaa, 2006). These authors 
demonstrated that dihydrotestosterone (DHT) significantly suppressed the expression of the 
catabolizing enzyme CYP24A1 in androgen-sensitive prostate cancer LNCaP cells. Their 
data demonstrated that DHT enhances the antiproliferative activity of vitamin D3 hormones 
by inhibiting their inactivating enzyme at physiological concentration of androgen. They 
suggested that the combined use of androgen and vitamin D3 metabolites could be a 
promising treatment for prostate cancer. 
6. Concluding remarks 
Recent research using cell models has revealed novel and tissue-specific actions of sex 
hormones and vitamin D3 in the regulation of enzymes in steroid metabolism. The active 
vitamin D hormone, calcitriol, has been found to affect genes in androgen and estrogen 
metabolism. Sex hormones regulate genes in neurosteroid metabolism and cholesterol 
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homeostasis, including the CYP7B1 and CYP27A1 genes. The data available on the actions 
of the multifunctional and widely expressed CYP7B1 indicate potentially important roles of 
this enzyme for regulation of neurosteroid levels in the CNS as well as for control of the 
levels of sex hormones important in estrogenic and androgenic signalling in various cell 
types and tissues.  Observed differences in effects and actions related to this enzyme reflect 
cell- and tissue-specificity of steroid-metabolizing enzymes of importance throughout the 
body. The new knowledge discussed in this review should be of importance for future 
research on brain function, endocrine signalling as well as treatment of estrogen- and 
androgen-dependent cancers, such as breast and prostate cancer. 
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can influence sex hormone production and action highlights the need to update our knowledge on the
mechanisms involved. This book provides a systematic and updated overview of the male/female sex-
hormones and their impact in the biology and physiology of various organs. Additionally, the book discusses
their positive and negative association with the pathophysiology of various diseases (e.g. osteoporosis,
cardiovascular-disease, hypogonadism, reproduction, cancer) and their therapeutic potential.
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